相关实验视频
Updated: May 15, 2025

09:48
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
293
乳腺癌中的细胞外囊泡介导化学抵抗:专注于miRNA载荷
Maria Chiara Ciferri1, Roberta Tasso1,2
1Department of Experimental Medicine (DIMES), University of Genova, Genova 16132, Italy.
Extracellular vesicles and circulating nucleic acids
|April 10, 2025
概括
细胞外囊泡 (EVs) 转移驱动乳腺癌化学抵抗的分子. 针对这些EV及其miRNA/蛋白质载荷可能会改善治疗反应并预测治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 细胞外囊泡 (EVs) 通过转移生物活性分子来调解细胞间的通信.
- 在乳腺癌化学抵抗的发展和进展中,EVs扮演着重要的角色.
- 通过EV的基因和蛋白质材料的水平转移有助于癌细胞的耐药性.
研究的目的:
- 审查细胞外囊泡 (EVs),特别是它们的miRNA载荷在推动乳腺癌药物耐药性的作用.
- 要突出EV介导的分子转移如何影响乳腺癌的治疗结果.
- 探索EVs作为预后因素和乳腺癌治疗中的治疗点的潜力.
主要方法:
- 文献综述专注于研究研究乳腺癌中的细胞外囊泡和化学抵抗.
- 通过EVs转移的分子载荷 (miRNAs, lncRNAs,蛋白质) 的分析.
- 检查EV载荷对细胞过程,如细胞亡,上皮细胞-介质细胞过渡 (EMT),血管生成和瘤微环境的影响.
主要成果:
- 来自耐化学反应细胞的EV携带miRNA和lncRNA,调节控制细胞增殖和存活的基因网络.
- 电动汽车货物抑制了亡,促进了EMT,增强了血管生成,并调节了瘤微环境,从而促进了耐药性.
- 此外,EV还转移功能性蛋白质,如P-糖蛋白和HSP70,影响细胞代谢和生存.
结论:
- 细胞外囊泡是乳腺癌化学抵抗的重要媒介,通过多种分子载荷的转移.
- EVs具有作为预后生物标志物的潜力,用于预测乳腺癌患者的治疗反应.
- 针对电动汽车及其货物是一个有希望的治疗策略,可能与传统疗法相结合.
更多相关视频
相关概念视频
MicroRNAs
2.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
2.9K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K

